Hengrui Pharma (01276) is experiencing a significant surge in its stock price, soaring 5.10% during the intraday trading session. This robust performance comes on the heels of the company's impressive financial results and a major breakthrough in its pharmaceutical development.

The company recently released its financial report for the first three quarters of 2025, showcasing strong growth. Hengrui Pharma reported a revenue of RMB 23.188 billion, marking a 14.85% increase year-on-year. More notably, the net profit attributable to shareholders reached RMB 5.751 billion, representing a substantial 24.5% growth compared to the same period last year. The basic earnings per share stood at an impressive RMB 0.89, further underlining the company's solid financial performance.

Adding to the positive sentiment, Hengrui Pharma announced a significant milestone in its drug development efforts. The company's subsidiary, Shandong Sandoz Pharmaceuticals, received approval from China's National Medical Products Administration for its self-developed diabetes drug, Ruiletang®. This innovative medication is China's first domestically developed triple-combination oral antidiabetic drug, positioning Hengrui Pharma at the forefront of diabetes treatment innovation in the country. The drug is designed to improve blood sugar control in adult patients with type 2 diabetes who have not achieved adequate glycemic control with metformin hydrochloride treatment alone.